Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
April 16 2018 - 8:36AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING
|
|
OMB
APPROVAL
|
|
OMB
Number: 3235-0058
Expires: August 31, 2015
Estimated average burden
hours per response.... 2.50
|
|
|
|
SEC
FILE NUMBER
333-172744
|
|
|
|
CUSIP
NUMBER
36316C106
|
(Check one):
☐ Form
10-K ☐ Form 20-F ☐ Form 11-K ☒ Form
10-Q ☐ Form 10-D ☐ Form N-SAR ☐ Form
N-CSR
|
For Period Ended:
February 28, 2018
|
|
|
|
☐
Transition Report on Form 10-K
☐
Transition Report on Form 20-F
☐
Transition Report on Form 11-K
☐
Transition Report on Form 10-Q
☐
Transition Report on Form N-SAR
|
|
|
|
For the Transition Period Ended:_____________
|
Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.
|
If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT INFORMATION
GALA PHARMACEUTICAL, INC.
Full Name of
Registrant
N/A
Former Name if Applicable
2780 South Jones Blvd. #3725
Address of Principal Executive Office
(Street and Number)
Las Vegas, Nevada 89146
City, State and Zip Code
PART II — RULES 12b-25(b) AND (c)
If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
x
|
(a)
|
The reason described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense
|
|
|
(b)
|
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
|
|
|
(c)
|
The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q,
10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.
The company's auditor will complete their review of the
financial information approximately April 19, 2018.
PART IV — OTHER INFORMATION
(1)
|
Name and telephone number of person to contact in regard to this notification
|
|
Owen Naccarato
|
949
|
851-9261
|
|
(Name)
|
(Area Code)
|
(Telephone Number)
|
(2)
|
Have all other periodic reports required under Section 13 or 15(d)
of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for
such shorter period that the registrant was required to file such report(s) been filed ? If answer is no, identify report(s).
☒ Yes
☐ No
|
|
|
(3)
|
Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject
report or portion thereof?
☐ Yes ☒ No
If so, attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.
|
GALA PHARMACEUTICAL,
INC.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on
its behalf by the undersigned hereunto duly authorized.
|
|
|
Date:
April 16, 2018
|
By:
|
/s/ Maqsood Rehman
|
|
|
Maqsood Rehman
|
|
|
Title: Chief Executive Officer
|
|